# US 2021/0196738 A1 · Pharmaceutical composition comprising a colloidal dispersion and a therapeutic agent and methods and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196738 A1
- Document ID: US20210196738A1
- Status: Published application
- Kind: A1
- Application number: 16/771,779
- Filed: 2018-12-21
- Published: 2021-07-01
- Earliest claimed: 2017-12-21
- Assignees: Prebona AB
- Applicants: Prebona AB
- Inventors: Claes AHLNECK; Dan ANDERSSON; Jan-Erik OTTERSTEDT
- Web page: https://patentgrep.com/patent/US20210196738A1

## CPC

- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A01N 25/08: containing solids as carriers or diluents
- A61K 9/10: Dispersions; Emulsions
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/351: not condensed with another ring
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 33/38: Silver; Compounds thereof
- A61K 47/02: Inorganic compounds
- A61P 31/04: Antibacterial agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to pharmaceutical compositions comprising colloidal dispersions of silica particles to which silver ions have been adsorbed in combination with therapeutically active agents. It is also related to a kit of parts, uses and medical methods of treatment involving said pharmaceutical compositions or the components of said pharmaceutical composition. The invention provides means for alternative treatment strategies for bacterial infections to lessen the need for traditional antibiotics.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a) an antibiotic agent; and,
b) a colloidal dispersion of particles of silica having a particle size from 3 nm to 100 nm to which particles silver ions have been adsorbed.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the antibiotic agent is selected from the group consisting of aminoglycosides, beta-lactams, steroid antibiotics and tetracyclines.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said antibiotic agent is an aminoglycoside.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said particles of silica have a particle size of 3 to 25 nm.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the silver ions are present in an amount of 0.05 ppm to 50 ppm by weight of the colloidal dispersion.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the silver ions have been adsorbed in an amount of 0.0005 to more than 5 silver ions per nm2.

### Claim 7

A kit of parts comprising:
a) a pharmaceutical formulation including an antibiotic agent, optionally in admixture with a pharmaceutically acceptable excipient; and
b) a colloidal dispersion comprising particles of silica having a particle size from 3 nm to 100 nm to which particles silver ions have been adsorbed.

### Claim 8 (depends on 7)

The kit of claim 7, wherein the antibiotic agent is selected from the group consisting of aminoglycosides, beta-lactams, steroid antibiotics and tetracyclines.

### Claim 9 (depends on 8)

The kit of claim 8, wherein said antibiotic agent is an aminoglycoside.

### Claim 10 (depends on 7)

The kit of claim 7, wherein said particles of silica have a particle size of 3 to 25 nm.

### Claim 11 (depends on 7)

The kit of claim 7, wherein the silver ions are present in an amount of 0.05 ppm to 50 ppm by weight of the colloidal dispersion.

### Claim 12 (depends on 7)

The kit of claim 7, wherein the silver ions have been adsorbed in an amount of 0.0005 to more than 5 silver ions per nm2.

### Claim at position 13

13-23. (canceled)

### Claim 24

A method for the treatment of a bacterial infection, said method comprising administering a therapeutically effective amount of an antibiotic agent and a colloidal dispersion of particles of silica having a particle size from 3 nm to 100 nm to which particles silver ions have been adsorbed, to a subject in need thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the antibiotic agent is selected from the group consisting of aminoglycosides, beta-lactams, steroid antibiotics and tetracyclines.

### Claim 26 (depends on 24, 25)

The method of claim 24 or 25, wherein said bacterial infection is an infection caused by gram-positive or gram-negative bacteria.

### Claim 27 (depends on 24)

The method of claim 24, wherein the bacterial infection is an infection by Staphylococcous aureus, Pseudomonas aeruginosa, Salmonella enterica, Escherichia coli, or Acinetobacter baumannii.

### Claim 28 (depends on 24)

The method of claim 24, wherein said antibiotic agent is an aminoglycoside, such as Gentamycin or Tobramycin, and the bacterial infection is an infection by E. coli.

### Claim 29 (depends on 24)

The method of claim 24, wherein said antibiotic agent is an aminoglycoside, and the bacterial infection is an infection by Salmonella enterica.

### Claim 30 (depends on 24)

The method of claim 24, wherein said antibiotic agent is a steroid antibiotic, such as Mupirocin or Fusidic acid, and the bacterial infection is an infection by Staphylococcous aureus.

### Claim 31 (depends on 24)

The method of claim 24, wherein said administration is oral, rectal, topical, subcutaneous, intramuscular or pulmonary.

### Claim 32 (depends on 24)

The method of claim 24, wherein the colloidal dispersion and the antibiotic agent are administered in sequence or concurrently.

### Claim 33 (depends on 24)

The method of claim 24, wherein the antibiotic agent and the colloidal dispersion are present in the same pharmaceutical composition.

### Claim 34 (depends on 24)

The method of claim 24, wherein said treatment is for the treatment of a bacterial infection of the skin or of the mucosa.
